Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches

Cancer Treatment Reviews
M ScartozziS Cascinu

Abstract

Both the availability of multiple treatment modalities and novel therapeutic targets make the correct prognostic stratification and the identification of truly predictive factors an issue of major debate in gastric cancer. Along with "classic" prognostic factors such as those related to the diffusion of the tumour at diagnosis (i.e., depth of gastric wall infiltration, locoregional lymph nodes or distant metastases) or those concerning the pathologic characteristics of the tumour, other, innovative, factors should be considered if a better definition of the characteristics of the tumour is to be given. These biological factors are often derived from the genetic process, which is thought to represent a crucial step to gastric cancer (DNA copy number changes, microsatellite instability, thymidilate synthase, E-cadherin, beta-catenin, mucin antigen, p53, c-erb B-2, COX-2, matrix metalloproteinases, VEGFR and EGFR). Some of those putative prognostic indicators can also be considered predictive of response to therapy as they are a molecular target either to chemotherapeutics (i.e., thymidilate synthase that is targeted by 5FU) or to a new class of antineoplastic molecules (i.e., c-erb B-2 targeted by trastuzumab, COX-2 by NSAIDs, ma...Continue Reading

References

Jun 1, 1992·Protein Science : a Publication of the Protein Society·K M PerryR M Stroud
Dec 1, 1994·International Journal of Cancer. Journal International Du Cancer·H KuniyasuE Tahara
Jul 1, 1993·Cancer Genetics and Cytogenetics·R SerucaM Sobrinho-Simões
Feb 24, 2001·Virchows Archiv : an International Journal of Pathology·Y J ChungM G Rhyu
Jan 17, 2002·The Journal of Pathology·Bastiaan P van ReesG Johan A Offerhaus
May 31, 2002·Expert Opinion on Investigational Drugs·Gordon Strathdee, Robert Brown
Aug 3, 2002·Oncogene·Adam R Karpf, David A Jones
Aug 9, 2002·Journal of Gastroenterology and Hepatology·Hideaki H IshiiYoshiro Ebihara
Aug 23, 2002·Seminars in Cancer Biology·Gordon Strathdee
Sep 5, 2002·The Journal of Pathology·Daniela FurlanAnna Maria Chiaravalli
Sep 11, 2002·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Jesper Worm, Per Guldberg
Sep 28, 2002·Genes, Chromosomes & Cancer·Chew-Wun WuJeou-Yuan Chen
Nov 7, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Goffin, E Eisenhauer
Nov 12, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·Suya YangMary E Gerritsen
Mar 29, 2003·Expert Opinion on Biological Therapy·Julia Glade-BenderDarrell J Yamashiro
Apr 8, 2003·Current Medicinal Chemistry. Anti-cancer Agents·S ShinkarukG Déléris
May 2, 2003·Nature Reviews. Cancer·Daniel B LongleyPatrick G Johnston
Aug 5, 2004·Journal of the National Cancer Institute·Andrei OugolkovToshinari Minamoto
Sep 12, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federico RojoJosé Baselga

❮ Previous
Next ❯

Citations

Apr 29, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Gravalos, A Jimeno
Nov 8, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E BriaA Scarpa
Jun 10, 2010·Folia Histochemica Et Cytobiologica·Jolanta CzyzewskaAndrzej Kemona
Jan 22, 2011·World Journal of Gastroenterology : WJG·Stefania NobiliGabriella Nesi
Jun 22, 2006·Future Oncology·Gianpaolo SurianoRaquel Seruca
Nov 16, 2006·Annals of Surgical Oncology·Alberto MarchetDonato Nitti
Jul 3, 2015·Molecular and Clinical Oncology·Melike Dinccelik-AslanAjlan Tukun
Jun 6, 2008·Mayo Clinic Proceedings·Nikhil Khushalani
Nov 22, 2011·Surgical Oncology Clinics of North America·Nikhil I Khushalani
Apr 5, 2011·Ultrasound in Medicine & Biology·Hamidreza MiriAmir-Ali Shahbazfar
May 20, 2008·Surgical Oncology Clinics of North America·Donato NittiMario Lise
May 17, 2005·Journal of Surgical Oncology·Henry T LynchDavid Huntsman
Jan 11, 2007·The Journal of Obstetrics and Gynaecology Research·Naoki SasakiYoshihiro Kikuchi
Nov 25, 2011·Proteomics·Mustafa A BarbhuiyaAkhilesh Pandey
Sep 13, 2005·Gene·Michael Stock, Florian Otto
Jan 30, 2016·Journal of Gastroenterology and Hepatology·Soo-Kyung ParkSeung-Jae Myung
Dec 16, 2011·The Journal of Clinical Endocrinology and Metabolism·Leonie J M HerrmannStefanie Hahner
Jan 14, 2020·Molecular and Clinical Oncology·Adriano Carneiro da CostaJosé Luiz Figueiredo
May 24, 2006·World Journal of Gastroenterology : WJG·Yun Dai, Wei-Hong Wang
Feb 10, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rossella LibèJérôme Bertherat
Jun 9, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L OttiniA Russo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis